Precision Medicine

Researchers have developed a new AI tool called neural iterative selection-expansion (NISE) that designs proteins to bind specific drugs. Unlike traditional methods that rely on lengthy laboratory testing, NISE uses an AI-guided design process to quickly predict and improve protein-drug interactions. In early experiments, nearly all of the AI-designed proteins successfully bound to their target […]

Results from the phase 2 MERIDIAN trial show that circulating tumor DNA (ctDNA) can help detect and guide treatment of residual disease in patients with locally advanced head and neck squamous cell carcinoma. Researchers used the RaDaR assay, a personalized blood test, to monitor patients after treatment. The test showed very high accuracy, with positive

Real-world data and circulating tumor DNA (ctDNA) are helping doctors detect and overcome treatment resistance in EGFR-mutated non-small cell lung cancer. Resistance patterns vary by treatment. With osimertinib alone, common causes include MET amplification and secondary EGFR mutations. In combination therapy, such as osimertinib plus chemotherapy, resistance can also involve small cell transformation. Newer combinations

Colorectal cancer research in early 2026 is increasingly focused on precision medicine, using biomarkers to guide treatment decisions for different patient groups. One major approach is using circulating tumor DNA (ctDNA) to decide who needs chemotherapy after surgery. Patients with no detectable ctDNA may safely avoid chemotherapy, while those with positive ctDNA—indicating a higher risk

Management of HPV-positive oropharyngeal cancer is focusing on keeping high cure rates while reducing long-term side effects. These tumors respond well to therapy, but lowering treatment intensity—called “de-intensification”—must be done carefully, as removing chemotherapy early has led to worse outcomes. Clinicians are improving quality of life using precision radiation techniques like Proton Therapy to spare

Multiple myeloma treatment is shifting toward precision medicine, where care is tailored to each individual patient instead of broad risk groups. A new artificial intelligence tool called CORAL-histomorph can analyze standard bone marrow biopsy images and predict key genetic abnormalities—such as the 11;14 translocation—with over 90% accuracy. This is significant because it removes the need

New data shows that the i31-SLNB genomic test can help identify melanoma patients who may safely skip sentinel lymph node biopsy. The test is part of the DecisionDx-Melanoma and combines a 31-gene profile with clinical factors such as age and tumor thickness to predict whether cancer has spread to lymph nodes. In a study of

A new study suggests that treatment for Stage III Colon Cancer may need to be more personalized. Standard care usually includes surgery followed by adjuvant chemotherapy, such as CAPOX or Capecitabine, but about 30% of patients still experience cancer recurrence. Researchers analyzed 259 patients to identify biological markers that may predict which tumors will resist

A study compared two standard first-line chemotherapy regimens for advanced Pancreatic Ductal Adenocarcinoma (PDAC): FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP), examining how genetic markers, including BRCA2 and Tumor Mutational Burden (TMB), affect outcomes. In the overall population, GnP showed a slight survival advantage over FFX, supporting its use as a standard first-line therapy. Patients